Clinical Trial

Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the safety and efficacy of neoadjuvant HRS-4642 plus chemotherapy with or without adebrelimab in patients with pancreatic ductal adenocarcinoma.
Trial Details
NCT Number NCT07691593
Lead Sponsor Changhai Hospital
Conditions Pancreatic Cancer
Enrollment 60 participants
Start Date 2026-06
Primary Completion 2027-10 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-09